Evidence map›Paper›PMID 36158661›Full record

ReviewFrontiers in oncology2022

Ferroptosis: A potential opportunity for intervention of pre-metastatic niche.

Shenghua Zhuo, Liangwang Yang, Shenbo Chen, Caiying Tang, Weicheng Li, Zhenzhong Gao, Jigao Feng, Kun Yang

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. CircDUSP22 Attenuates the Ferroptosis of Prostate Cancer CellsCombinatorial chemistry & high throughput screening · 2025
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shenghua ZhuoDepartment of Neurosurgery, First Affiliated Hospital of Hainan Medical University, Haikou, China.
Liangwang YangDepartment of Neurosurgery, First Affiliated Hospital of Hainan Medical University, Haikou, China.
Shenbo ChenDepartment of Neurosurgery, First Affiliated Hospital of Hainan Medical University, Haikou, China.
Caiying TangDepartment of Neurosurgery, First Affiliated Hospital of Hainan Medical University, Haikou, China.
Weicheng LiDepartment of Neurosurgery, First Affiliated Hospital of Hainan Medical University, Haikou, China.
Zhenzhong GaoDepartment of Neurosurgery, First Affiliated Hospital of Hainan Medical University, Haikou, China.
Jigao FengDepartment of Neurosurgery, Second Affiliated Hospital of Hainan Medical University, Haikou, China.
Kun YangDepartment of Neurosurgery, First Affiliated Hospital of Hainan Medical University, Haikou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is widely thought that the tumor microenvironment (TME) provides the "soil" for malignant tumors to survive. Prior to metastasis, the interaction at the host site between factors secreted by primary tumors, bone-marrow-derived cells, with stromal components initiates and establishes a pre-metastatic niche (PMN) characterized by immunosuppression, inflammation, angiogenesis and vascular permeability, as well as lymphangiogenesis, reprogramming and organotropism. Ferroptosis is a non-apoptotic cell death characterized by iron-dependent lipid peroxidation and metabolic constraints. Ferroptotic cancer cells release various signal molecules into the TME to either suppress or promote tumor progression. This review highlights the important role played by ferroptosis in PMN, focusing on the relationship between ferroptosis and PMN characteristics, and discusses future research directions.

Indexed as

ferroptosisimmune escapepre-metastatic nichetherapeutic strategiestumor

Identifiers

PMID36158661
PMCPMC9500500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.